唑来膦酸
医学
双膦酸盐
脊髓压迫
前列腺癌
病理性骨折
骨病
外科
泌尿科
骨痛
泌尿生殖系统
内科学
肿瘤科
骨转移
骨质疏松症
癌症
脊髓
精神科
作者
Fred Saad,Allan Lipton
出处
期刊:BJUI
[Wiley]
日期:2005-10-13
卷期号:96 (7): 964-969
被引量:53
标识
DOI:10.1111/j.1464-410x.2005.05740.x
摘要
Patients with metastatic bone disease often have severe bone pain and debilitating skeletal complications. Zoledronic acid is the only bisphosphonate shown to be safe and effective in reducing skeletal‐related events (SREs), including pathological fractures, spinal cord compression, and radiation or surgery to bone in patients with bone metastases from advanced prostate cancer or renal cell carcinoma (RCC). In both tumour types, zoledronic acid significantly decreased the overall risk of developing an SRE, delayed their onset and significantly reduced the incidence of SREs compared with placebo. In patients with RCC, zoledronic acid also significantly delayed the time to progression of bone lesions by 5 months compared with placebo. Zoledronic acid is safe and well tolerated with long‐term use.
科研通智能强力驱动
Strongly Powered by AbleSci AI